Damanhour university
Beheira, Damanhour, 22511, Egypt
NCT Number: NCT07668076
the study aims to evaluate the cardioprotective effect of atorvastatin in breast cancer female patients treated with doxorubicin based chemotherapy
Looking for future studies?
Notify Me18 year–65 year
Female
Interventional
Phase 2
Beheira, Damanhour, 22511, Egypt
female patients with newly diagnosed breast cancer, who are candidates for AC protocol will be recruited from Damanhour oncology center.
All enrolled patients will be randomly assigned into 2 arms:
All patients will be submitted to:
All patients will be followed up during 3 months' period. At the end of 3 months, Serum samples will be collected from patients for measuring the biomarkers. Statistical tests appropriate to the study design will be conducted to evaluate the significance of the results. 8. Measuring outcome: The primary outcome is the change of serum levels of the measured cardiac biomarkers after 4 cycles of AC regimen.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
atorvastatin 40 mg orally once daily for 3 months.
Time frame: baseline and 3 months ( after completion of 4 cycles of AC chemotherapy)
change from baseline in Serum levels of N-terminal pro-brain natriuretic peptide (NT-proBNP), suppression of tumorigenicity-2 (ST2), myeloperoxidase (MPO), and cholesterol using enzyme-linked immunosorbent assay (ELISA) kits and standard biochemical methods according to manufacturer instructions
Damanhour University
Other
The Potential Cardioprotective Effect of Addition of Atorvastatin in Breast Cancer Patients Treated With Doxorubicin-based Chemotherapy
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02796365
Behavior, Breast Cancer
Detroit, Michigan, United States
View Trial DetailsNCT06427226
Breast Cancer, Breast Diseases
Alexandria, Bab Sharqi, Egypt
View Trial DetailsNCT07370506
Breast Cancer, Breast Diseases
Tanta, El Gharbia, Egypt
View Trial DetailsNCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial Details